Targets › HTR1A
19 programs from 16 companies in 36 trials: 10 Phase 3, 10 Phase 1, 8 Phase 4, 8 Phase 2; Psychiatry, Neurology, Oncology; next expected readout Dec 2026.
G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. (UniProt, P08908)
Open in Phaseline: the race on HTR1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| VA Office of Research and Development | Buspirone Serotonin 1a (5-HT1a) receptor partial agonist | HTR1A | Phase 4 | Sleep Disordered Breathing | Dec 2026 |
| Valenta Pharm JSC | Vespireit 5-HT1A receptor agonist | HTR1A | Phase 4 | Vertigo | Dec 2026 |
| Massachusetts General Hospital | Buspirone Serotonin 1a (5-HT1a) receptor partial agonist | HTR1A | Phase 4 | Depression; Anxiety | Jul 2028 |
| Northwell Health | aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 4 | Psychosis; Acute; Schizophenia Disorder | Dec 2029 |
| Massachusetts General Hospital | Aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 4 | Bipolar I Disorder | Feb 2030 |
| University of California, Los Angeles | CBD 20 mg GABA-A receptor; anion channel positive allosteric modulator | HTR1A, GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, SLC1A2, SLC1A3 | Phase 3 | Spinocerebellar Ataxias; Non-healing Wound; Sleep Apnea, Obstructive; Cervical Spinal Cord Injury … | Dec 2026 |
| Shanghai Mental Health Center | Aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 3 | Treatment-resistant Schizophrenia; Obsessive-Compulsive Disorder | Jun 2027 |
| Otsuka | Brexpiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 3 | Acute Schizophrenia | Sep 2027 |
| Vanda Pharmaceuticals | Milsaperidone 5-HT1A receptor partial agonist | HTR1A | Phase 3 | Major Depressive Disorder (MDD) | Mar 2028 |
| Otsuka | Ulotaront (SEP-363856) Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist | HTR1A, TAAR1 | Phase 3 | Schizophrenia; Generalized Anxiety Disorder | Oct 2028 |
| Takeda | Vortioxetine Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist | HTR1A, SLC6A4, HTR3A | Phase 3 | Major Depressive Disorder; Glioblastoma; Depression | Sep 2029 |
| University of Maryland, Baltimore | Buspirone Serotonin 1a (5-HT1a) receptor partial agonist | HTR1A | Phase 2 | Opioid Use Disorder | Jan 2027 |
| Spaulding Rehabilitation Hospital | Buspirone Hydrochloride Serotonin 1a (5-HT1a) receptor partial agonist | HTR1A | Phase 2 | Spinal Cord Injuries | Apr 2027 |
| Memorial Sloan Kettering Cancer Center | Flibanserin Serotonin 1A receptor agonist, serotonin 2A receptor antagonist, and serotonin reuptake in | HTR1A, HTR2A, SLC6A4 | Phase 2 | Breast Cancer | Oct 2027 |
| Yale University | Dimethyltryptamine (DMT) Serotonin 5-HT receptor agonist; endogenous psychedelic compound | HTR1A, HTR1B, HTR1D, HTR2A | Phase 1 | Major Depressive Disorder; Alcohol Use Disorder (AUD) | Dec 2026 |
| Joshua A. Lile, Ph.D. | Cobenfy M1 muscarinic receptor agonist and 5-HT1A receptor partial agonist | HTR1A, CHRM1 | Phase 1 | Cocaine Use Disorder (CUD) | Jun 2032 |
| Sichuan Kelun Pharmaceutical | Brexpiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 1 | Schizophrenia Disorders; Major Depressive Disorder; Bipolar Depression; Alcohol Use Disorder | – |
| University Hospital, Basel, Switzerland | DMT 5-HT receptor agonist, primarily 5-HT1A and 5-HT7 | HTR1A, HTR1B, HTR1D, HTR5A, HTR7 | Phase 1 | Healthy | – |
| University Hospital, Basel, Switzerland | LSD 5-HT receptor agonist, primarily 5-HT1A and 5-HT7 | HTR1A, HTR1B, HTR1D, HTR5A, HTR7 | Phase 1 | Healthy | – |
Generalized Anxiety Disorder (3) Major Depressive Disorder (3) Depression (2) Healthy (2) Schizophrenia (1) Anxiety (1) Breast Cancer (1) Major Depressive Disorder (MDD) (1) Schizophrenia Disorders (1) Bipolar Depression (1) Alcohol Use Disorder (1) Spinocerebellar Ataxias (1)
small molecule (18), protein or peptide (1)
Otsuka (2) Massachusetts General Hospital (2) University Hospital, Basel, Switzerland (2) Memorial Sloan Kettering Cancer Center (1) Vanda Pharmaceuticals (1) Sichuan Kelun Pharmaceutical (1) University of California, Los Angeles (1) VA Office of Research and Development (1) Northwell Health (1) University of Maryland, Baltimore (1) Takeda (1) Shanghai Mental Health Center (1) Yale University (1) Joshua A. Lile, Ph.D. (1) Spaulding Rehabilitation Hospital (1) Valenta Pharm JSC (1)
HTR2A (7) DRD2 (5) HTR1B (3) HTR1D (3) SLC6A4 (2) HTR5A (2) HTR7 (2) TAAR1 (1) GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.